Martin Brandl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8885860/publications.pdf

Version: 2024-02-01

109 papers	4,453 citations	81900 39 h-index	123424 61 g-index
111 all docs	111 docs citations	111 times ranked	4771 citing authors

#	Article	IF	Citations
1	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. European Journal of Pharmaceutical Sciences, 2019, 137, 104967.	4.0	222
2	Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. International Journal of Pharmaceutics, 2001, 223, 55-68.	5.2	207
3	Biopharmaceutical classification of poorly soluble drugs with respect to â€œenabling formulationsâ€: European Journal of Pharmaceutical Sciences, 2013, 50, 8-16.	4.0	158
4	Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion. European Journal of Pharmaceutical Sciences, 2006, 27, 80-90.	4.0	148
5	Drug permeability profiling using cell-free permeation tools: Overview and applications. European Journal of Pharmaceutical Sciences, 2018, 119, 219-233.	4.0	139
6	Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. International Journal of Pharmaceutics, 2012, 437, 288-293.	5.2	129
7	In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives. European Journal of Pharmaceutical Sciences, 2012, 45, 235-250.	4.0	113
8	Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. International Journal of Pharmaceutics, 2012, 439, 49-62.	5.2	104
9	Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. European Journal of Pharmaceutical Sciences, 2010, 40, 25-32.	4.0	96
10	5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. International Journal of Pharmaceutics, 2003, 256, 123-131.	5.2	92
11	What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?. Journal of Pharmaceutical Sciences, 2014, 103, 1779-1786.	3.3	91
12	Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemotherapy and Pharmacology, 2002, 49, 356-366.	2.3	72
13	Liposome Size Analysis by Dynamic/Static Light Scattering upon Size Exclusion-/Field Flow-Fractionation. Journal of Nanoscience and Nanotechnology, 2006, 6, 3025-3031.	0.9	69
14	Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid. Chemistry and Physics of Lipids, 2010, 163, 141-147.	3.2	69
15	Oral bioavailability enhancement through supersaturation: an update and meta-analysis. Expert Opinion on Drug Delivery, 2017, 14, 403-426.	5.0	68
16	Drug permeability across a phospholipid vesicle-based barrier. European Journal of Pharmaceutical Sciences, 2006, 28, 336-343.	4.0	67
17	In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 359-365.	2.8	67
18	Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 416-422.	4.3	67

#	Article	IF	Citations
19	Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 327-333.	4.3	66
20	Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. European Journal of Pharmaceutical Sciences, 2012, 47, 16-20.	4.0	61
21	In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. Journal of Pharmacy and Pharmacology, 2011, 63, 1022-1030.	2.4	56
22	Solubilization of ibuprofen with Î²-cyclodextrin derivatives: Energetic and structural studies. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 446-451.	2.8	56
23	Generation of contrast-carrying liposomes of defined size with a new continuous high pressure extrusion method. International Journal of Pharmaceutics, 1995, 117, 1-12.	5.2	53
24	Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. European Journal of Pharmaceutical Sciences, 2012, 45, 613-623.	4.0	51
25	Biodistribution and Computed tomography Blood-Pool Imaging Properties of Polyethylene Glycol-Coated Iopromide-Carrying Liposomes. Investigative Radiology, 1997, 32, 44-50.	6.2	51
26	Asymmetric flow fieldâ€flow fractionation of liposomes: optimization of fractionation variables. Journal of Separation Science, 2009, 32, 1465-1470.	2.5	49
27	Effect of hydroxypropyl-?-cyclodextrin-complexation and pH on solubility of camptothecin. International Journal of Pharmaceutics, 2004, 284, 61-68.	5.2	48
28	Drug permeability across a phospholipid vesicle-based barrier. European Journal of Pharmaceutical Sciences, 2008, 34, 173-180.	4.0	48
29	Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity. Journal of Biological Chemistry, 2012, 287, 233-244.	3.4	47
30	Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. European Journal of Pharmaceutical Sciences, 2017, 96, 20-27.	4.0	47
31	Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation. Journal of Controlled Release, 2010, 142, 319-325.	9.9	46
32	Liposomes with nifedipine and nifedipine-cyclodextrin complex: calorimetrical and plasma stability comparison. European Journal of Pharmaceutical Sciences, 1996, 4, 359-366.	4.0	45
33	Altered Activity and Physicochemical Properties of Short Cationic Antimicrobial Peptides by Incorporation of Arginine Analogues. Molecular Pharmaceutics, 2009, 6, 996-1005.	4.6	45
34	Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. Journal of Liposome Research, 2014, 24, 323-335.	3.3	44
35	Preparation and characterization of semi-solid phospholipid dispersions and dilutions thereof. International Journal of Pharmaceutics, 1998, 170, 187-199.	5.2	43
36	Steam sterilisation of vesicular phospholipid gels. International Journal of Pharmaceutics, 2001, 217, 161-172.	5.2	42

#	Article	IF	Citations
37	In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. Journal of Pharmacy and Pharmacology, 2010, 62, 1591-1598.	2.4	42
38	Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine. European Journal of Pharmaceutical Sciences, 2011, 42, 380-386.	4.0	40
39	Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drugâ€“membrane interactions and the effect of agitation on the barrier integrity and on the permeability. European Journal of Pharmaceutical Sciences, 2007, 30, 324-332.	4.0	39
40	Morphology of semisolid aqueous phosphatidylcholine dispersions, a freeze fracture electron microscopy study. Chemistry and Physics of Lipids, 1997, 87, 65-72.	3.2	38
41	The Effects of Temperature and Growth Phase on the Lipidomes of Sulfolobus islandicus and Sulfolobus tokodaii. Life, 2015, 5, 1539-1566.	2.4	38
42	Asymmetric flow fieldâ€flow fractionation of liposomes: 2. Concentration detection and adsorptive loss phenomena. Journal of Separation Science, 2009, 32, 3555-3561.	2.5	37
43	The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. International Journal of Nanomedicine, 2012, 7, 5757.	6.7	37
44	Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis. European Journal of Pharmaceutical Sciences, 2015, 80, 89-110.	4.0	37
45	Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-InÂVitro Permeability Enhancement. Journal of Pharmaceutical Sciences, 2016, 105, 1113-1123.	3.3	37
46	Physicochemical characterization of liposomes after ultrasound exposure â€“ Mechanisms of drug release. Journal of Pharmaceutical and Biomedical Analysis, 2013, 78-79, 118-122.	2.8	36
47	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Fieldâ€“Flow Fractionation/Multiangle Laser Light Scattering. Journal of Pharmaceutical Sciences, 2016, 105, 2832-2839.	3.3	36
48	Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. European Journal of Pharmaceutical Sciences, 2004, 21, 191-196.	4.0	35
49	Structural characterization of ether lipids from the archaeonSulfolobus islandicusby high-resolution shotgun lipidomics. Journal of Mass Spectrometry, 2015, 50, 476-487.	1.6	35
50	Archaeal lipids in oral delivery of therapeutic peptides. European Journal of Pharmaceutical Sciences, 2017, 108, 101-110.	4.0	35
51	Drug Permeability Profiling Using the Novel PermeapadÂ® 96-Well Plate. Pharmaceutical Research, 2020, 37, 93.	3.5	35
52	Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. International Journal of Pharmaceutics, 2011, 406, 114-116.	5.2	34
53	Filter-extruded liposomes revisited: a study into size distributions and morphologies in relation to lipid-composition and process parameters. Journal of Liposome Research, 2016, 26, 11-20.	3.3	34
54	Erosion and controlled release properties of semisolid vesicular phospholipid dispersions. Journal of Controlled Release, 1998, 55, 261-270.	9.9	31

#	Article	IF	Citations
55	Preparation of liposomes using a Mini-Lab 8.30 H high-pressure homogenizer. International Journal of Pharmaceutics, 1993, 91, 69-74.	5.2	30
56	Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 439-448.	4.3	29
57	Asymmetrical flow field-flow fractionation with on-line detection for drug transfer studies: a feasibility study. Analytical and Bioanalytical Chemistry, 2014, 406, 7827-7839.	3.7	29
58	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	4.0	29
59	Vesicular Phospholipid Gels: A Technology Platform. Journal of Liposome Research, 2007, 17, 15-26.	3.3	28
60	Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. Journal of Liposome Research, 2013, 23, 70-81.	3.3	28
61	PermeaLoopâ„¢, a novel in vitro tool for small-scale drug-dissolution/permeation studies. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 247-251.	2.8	27
62	A method to determine the incorporation capacity of camptothecin in liposomes. AAPS PharmSciTech, 2004, 5, 30-37.	3.3	26
63	Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer activity: a screening method to identify maximum incorporation capacity. Journal of Liposome Research, 2011, 21, 272-278.	3.3	26
64	Liposomes containing lipids from Sulfolobus islandicus withstand intestinal bile salts: An approach for oral drug delivery?. International Journal of Pharmaceutics, 2015, 493, 63-69.	5.2	26
65	Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS PharmSciTech, 2003, 4, 500-505.	3.3	25
66	Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release â^'/transfer-assay. Journal of Controlled Release, 2016, 232, 228-237.	9.9	25
67	Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1196, 65-75.	2.6	24
68	Surface modification of continuously extruded contrast-carrying liposomes: Effect on their physical properties. International Journal of Pharmaceutics, 1996, 132, 9-21.	5.2	24
69	Camptothecin-catalyzed phospholipid hydrolysis in liposomes. International Journal of Pharmaceutics, 2005, 288, 73-80.	5.2	24
70	Evaluation of a dynamic dissolution/permeation model: Mutual influence of dissolution and barrier-flux under non-steady state conditions. International Journal of Pharmaceutics, 2017, 522, 50-57.	5.2	24
71	Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions. AAPS PharmSciTech, 2003, 4, 62-70.	3.3	23
72	A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib. European Journal of Pharmaceutical Sciences, 2019, 127, 199-207.	4.0	23

#	Article	IF	Citations
73	Oromucosal drug delivery: Trends in in-vitro biopharmaceutical assessment of new chemical entities and formulations. European Journal of Pharmaceutical Sciences, 2019, 128, 112-117.	4.0	22
74	Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. European Journal of Pharmaceutical Sciences, 2011, 43, 318-324.	4.0	21
75	Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids. International Journal of Pharmaceutics, 2000, 206, 43-53.	5.2	20
76	Determination of the size distribution of liposomes by SEC fractionation, and PCS analysis and enzymatic assay of lipid content. AAPS PharmSciTech, 2002, 3, 9-15.	3.3	20
77	The use of asymmetrical flow field-flow fractionation with on-line detection in the study of drug retention within liposomal nanocarriers and drug transfer kinetics. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 157-163.	2.8	20
78	Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anti-Cancer Drugs, 2004, 15, 899-906.	1.4	19
79	Dissolution/permeation with PermeaLoopâ„¢: Experience and IVIVC exemplified by dipyridamole enabling formulations. European Journal of Pharmaceutical Sciences, 2020, 154, 105532.	4.0	18
80	Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 963-969.	2.8	17
81	High-Throughput Dissolution/Permeation Screeningâ€"A 96-Well Two-Compartment Microplate Approach. Pharmaceutics, 2019, 11, 227.	4.5	17
82	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapadâ‡ membrane and in vivo absorption. European Journal of Pharmaceutical Sciences, 2020, 152, 105452.	4.0	17
83	A novel microdialysis-dissolution/permeation system for testing oral dosage forms: A proof-of-concept study. European Journal of Pharmaceutical Sciences, 2017, 96, 154-163.	4.0	16
84	Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anti-Cancer Drugs, 2002, 13, 797-805.	1.4	15
85	Characterization of co-existing colloidal structures in fasted state simulated fluids FaSSIF: A comparative study using AF4/MALLS, DLS and DOSY. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 531-536.	2.8	15
86	Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay. International Journal of Pharmaceutics, 2012, 422, 52-58.	5.2	14
87	Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188. Journal of Pharmacy and Pharmacology, 2012, 64, 1631-1637.	2.4	13
88	Co-existing colloidal phases in artificial intestinal fluids assessed by AF4/MALLS and DLS: A systematic study into cholate & (lyso-) phospholipid blends, incorporating celecoxib as a model drug. European Journal of Pharmaceutical Sciences, 2018, 120, 61-72.	4.0	13
89	Co-existing colloidal phases of human duodenal aspirates: Intraindividual fluctuations and interindividual variability in relation to molecular composition. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 22-29.	2.8	13
90	Dissolution/Permeation of Albendazole in the Presence of Cyclodextrin and Bile Salts: A Mechanistic In-Vitro Study into Factors Governing Oral Bioavailability. Journal of Pharmaceutical Sciences, 2021, , .	3.3	13

#	Article	IF	Citations
91	Detection of Lipopolysaccharides in Phospholipids and Liposomes Using the Limulus Test. Journal of Liposome Research, 1995, 5, 109-116.	3.3	11
92	Surfactants enhance recovery of poorly soluble drugs during microdialysis sampling: Implications for in vitro dissolution-/permeation-studies. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 586-592.	2.8	11
93	Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations. European Journal of Pharmaceutical Sciences, 2022, 174, 106166.	4.0	11
94	Biopredictive capability assessment of two dissolution/permeation assays, ÂµFLUXâ„¢ and PermeaLoopâ„¢, using supersaturating formulations of Posaconazole. European Journal of Pharmaceutical Sciences, 2022, 176, 106260.	4.0	11
95	Quantification of Degradation Products Formed during Heat Sterilization of Glucose Solutions by LC-MS/MS: Impact of Autoclaving Temperature and Duration on Degradation. Pharmaceuticals, 2021, 14, 1121.	3.8	10
96	Vesicular Phospholipid Gels. Methods in Molecular Biology, 2010, 605, 205-212.	0.9	9
97	Acute toxicity and depression of phagocytosis in vivo by liposomes: Influence of lysophosphatidylcholine. Life Sciences, 1994, 56, 99-106.	4.3	8
98	A new approach for a blood-brain barrier model based on phospholipid vesicles: Membrane development and siRNA-loaded nanoparticles permeability. Journal of Membrane Science, 2016, 503, 8-15.	8.2	8
99	Do Phospholipids Boost or Attenuate Drug Absorption? InÂVitro and InÂVivo Evaluation of Mono- and Diacyl Phospholipid-Based Solid Dispersions of Celecoxib. Journal of Pharmaceutical Sciences, 2021, 110, 198-207.	3.3	8
100	(Sub)micron particles forming in aqueous dispersions of amorphous solid dispersions of the poorly soluble drug ABT-199: A combined particle optical counting and field-flow fractionation study. European Journal of Pharmaceutical Sciences, 2020, 154, 105497.	4.0	7
101	Application of Asymmetrical Flow Field-Flow Fractionation for Characterizing the Size and Drug Release Kinetics of Theranostic Lipid Nanovesicles. International Journal of Molecular Sciences, 2021, 22, 10456.	4.1	7
102	Modulation of Paracellular-like Drug Transport across an Artificial Biomimetic Barrier by Osmotic Stress-Induced Liposome Shrinking. Pharmaceutics, 2022, 14, 721.	4.5	7
103	â€˜Stirred not Shaken!â€™ Comparing Agitation Methods for Permeability Studies Using a Novel Type of 96-Well Sandwich-Plates. Journal of Pharmaceutical Sciences, 2021, , .	3.3	6
104	Compressibility study of quaternary phospholipid blend monolayers. Colloids and Surfaces B: Biointerfaces, 2011, 85, 153-160.	5.0	4
105	Identification and quantification of glucose degradation products in heat-sterilized glucose solutions for parenteral use by thin-layer chromatography. PLoS ONE, 2021, 16, e0253811.	2.5	4
106	The influence of liquid intake on the performance of an amorphous solid dispersion in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 296-298.	4.3	3
107	Vesicular Phospholipid Gels. , 2006, , 241-260.		3
108	2. Solubility and supersaturation. , 2019, , 27-70.		2

#	Article	IF	Citations
109	Re article â€œEvaluation of limulus amebocyte lysate and recombinant endotoxin alternative assays for an assessment of endotoxin detection specificityâ€, published in European Journal of Pharmaceutical Sciences 159 (2021) 105716. European Journal of Pharmaceutical Sciences, 2021, 163, 105877.	4.0	1